AstraZeneca India s NSCLC drug Tagrisso receives marketing approval biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca India s anti-diabetic drug receives approval for CKD treatment
AstraZeneca India s anti-diabetic drug receives approval for CKD treatment
08 February 2021 | News AstraZeneca’s dapagliflozin is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with chronic kidney disease (CKD)
Source credit: Shutterstock
AstraZeneca India (AstraZeneca Pharma India Limited), a leading science-led biopharmaceutical company, announced that they have received marketing authorisation for their anti-diabetic drug dapagliflozin, in India for the treatment of patients of chronic kidney disease (CKD) up to Stage III. The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to nephrologists in India.
DCGI approves AstraZenecaâs eosinophilic asthma drug
DCGI approves AstraZenecaâs eosinophilic asthma drug
22 December 2020 | News
Source credit: AstraZeneca
AstraZeneca India, a leading science-led biopharmaceutical company, has received marketing authorisation from Drugs Controller General of India (DCGI) for - use of the original research medicine, Fasenra™ (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml subcutaneous administration only) in patients with severe asthma (eosinophilic asthma). Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
Fasenra™ is an add-on maintenance treatment for patients with severe eosinophilic asthma. It is designed to target cells in the body called eosinophils, which are a key cause of the eosinophilic subtype of asthma. Fasenra™is not an inhaler or a steroid and is administered once in 8 weeks under the skin
DCGI approves AstraZeneca India s eosinophilic asthma drug biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.